Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage
0
(0)

Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders.

Under their collaboration agreement, Ionis received $5 million for bringing the therapy, IONIS-JBI 1-2.5 Rx, to the clinical-trial stage.

Janssen is responsible for obtaining regulatory approval of the treatment worldwide, and commercializing it.

Ionis stands to gain up to $585 million more in milestone payments and license fees. It will also receive a percentage of the sales of any product that reaches the market.

Ionis specializes in RNA-focused therapies for patients with unmet medical needs, including those with gastrointestinal immune disorders and inflammatory bowel diseases.

Ionis used its proprietary antisense technology to develop IONIS-JBI 1-2.5 Rx.

An antisense therapy consists of snythetic RNA that binds to the messenger RNA a faulty gene produces. The binding inactivates the messenger RNA, turning the gene off. This silencing prevents the gene from producing the abnormal protein associated with a disease.

IONIS-JBI 1-2.5 Rx is the first oral antisense therapy for gastrointestinal immune disorders that Ionis has brought to the clinical-trial stage.

“We are pleased with the success of our collaboration with Janssen,” C. Frank Bennett, Ionis’ senior vice president of research, said in a press release. “In under two years, we have advanced a drug into clinical trials” and begun studying “a second drug development candidate, IONIS-JBI 1-2.5 Rx.”

“Our collaboration with Janssen combines Ionis’ broad applicability of our antisense technology with their expertise in GI [gastrointestinal] autoimmune disorders and therapeutic formulation,” Bennett added. An autoimmune disorder is one that involves the immune system attacking healthy tissue instead of invaders.

In June of 2017, Janssen announced a partnership with Protagonist Therapeutics to develop, manufacture and market a new treatment for the bowel diseases Crohn’s and ulcerative colitis.

The therapy candidate, PTG-200, is an IL-23 receptor antagonist. When the receptor and IL-23 protein bind, the interaction generates cell signals that promote the inflammation seen in bowel diseases. PTG-200 prevents the binding, short-circuiting the inflammation.

The U.S. Food and Drug Administration has accepted Protagonist’s Investigational New Drug application for PGG-200, paving the way for the therapy to enter clinical trials.

Protagonist delivered a presentation at the Digestive Disease Week conference in Chicago in May of 2017 showing that PTG-200 alleviated mice’s bowel disease.

Subscribe to IBD News Today’s free weekly newsletter to receive the latest updates on IONIS-JBI 1-2.5 Rx, PTG-200 and other IBD therapies. The newsletter will be sent directly to your email inbox.

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • BBT-401 trial data
  • fCAL Elisa protein test
  • Infliximab
  • antibodies, ulcerative colitis

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?